Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x. Epub 2013 Jan 15. PMID: 23320782.
Mitsuzuka K, Koie T, Narita S, Kaiho Y, Yoneyama T, Tsuchiya N, Kakoi N, Kawamura S, Tochigi T, Ohyama C, Habuchi T, Yamaguchi T, Arai Y. Changes in indications and oncological outcomes of radical prostatectomy after 2000--data from 1268 Japanese patients treated with radical prostatectomy between 2000 and 2009. Jpn J Clin Oncol. 2013 Aug;43(8):821-6. doi: 10.1093/jjco/hyt072. Epub 2013 May 31. PMID: 23729494.
Narita S, Mitsuzuka K, Yoneyama T, Tsuchiya N, Koie T, Kakoi N, Kawamura S, Kaiho Y, Ohyama C, Tochigi T, Yamaguchi T, Habuchi T, Arai Y. Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2013 Sep;16(3):271-6. doi: 10.1038/pcan.2013.16. Epub 2013 Jun 11. PMID: 23752230.
Mitsuzuka K, Koie T, Narita S, Kaiho Y, Yoneyama T, Kawamura S, Tochigi T, Ohyama C, Habuchi T, Arai Y. Is pelvic lymph node dissection required at radical prostatectomy for low-risk prostate cancer? Int J Urol. 2013 Nov;20(11):1092-6. doi: 10.1111/iju.12112. Epub 2013 Feb 6. PMID: 23387553.
Mitsuzuka K, Koie T, Narita S, Kaiho Y, Yoneyama T, Tsuchiya N, Kakoi N, Kawamura S, Tochigi T, Ohyama C, Habuchi T, Arai Y. Pathological and oncological outcomes of elderly men with clinically localized prostate cancer. Jpn J Clin Oncol. 2013 Dec;43(12):1238-42. doi: 10.1093/jjco/hyt143. Epub 2013 Sep 25. PMID: 24068712.
Mitsuzuka K, Koie T, Narita S, Kaiho Y, Yoneyama T, Tsuchiya N, Kakoi N, Kawamura S, Tochigi T, Ohyama C, Habuchi T, Arai Y. Are pathological and oncological outcomes of elderly men treated with radical prostatectomy worse than those of younger men? Matched-pair analysis between patients aged ＆lt;70 and ≥70 years. Jpn J Clin Oncol. 2014 Jun;44(6):587-92. doi: 10.1093/jjco/hyu038. Epub 2014 Apr 9. PMID: 24721676.
Mitsuzuka K, Arai Y. Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy. Int J Clin Oncol. 2014 Oct;19(5):793-9. doi: 10.1007/s10147-014-0738-7. Epub 2014 Aug 26. PMID: 25152091.
Koie T, Mitsuzuka K, Narita S, Yoneyama T, Kawamura S, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C. Efficiency of pretreatment risk stratification systems for prostate cancer in a Japanese population treated with radical prostatectomy. Int J Urol. 2015 Jan;22(1):70-3. doi: 10.1111/iju.12597. Epub 2014 Aug 13. PMID: 25115632.
Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y. Prostate- specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy. Int J Clin Oncol. 2015 Feb;20(1):176-81. doi: 10.1007/s10147-014-0696-0. Epub 2014 Apr 29. PMID: 24771079.
Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Ohyama C, Habuchi T, Arai Y. Lymphovascular invasion is significantly associated with biochemical relapse after radical prostatectomy even in patients with pT2N0 negative resection margin. Prostate Cancer Prostatic Dis. 2015 Mar;18(1):25-30. doi: 10.1038/pcan.2014.40. Epub 2014 Oct 21. PMID: 25330857.
Koie T, Mitsuzuka K, Narita S, Yoneyama T, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens. Scand J Urol. 2015 Apr;49(2):103-7. doi: 10.3109/21681805.2014.951959. Epub 2014 Aug 28. PMID: 25165894.
Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. Int J Clin Oncol. 2015 Oct;20(5):1018-25. doi: 10.1007/s10147-015-0802-y. Epub 2015 Feb 15. PMID: 25681879.
Narita S, Mitsuzuka K, Tsuchiya N, Koie T, Kawamura S, Ohyama C, Tochigi T, Yamaguchi T, Arai Y, Habuchi T; Michinoku Japan Urological Cancer Study Group. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy. Int J Urol. 2015 Nov;22(11):1029-35. doi: 10.1111/iju.12898. Epub 2015 Aug 20. PMID: 26290306.
Mitsuzuka K, Kyan A, Sato T, Orikasa K, Miyazato M, Aoki H, Kakoi N, Narita S, Koie T, Namima T, Toyoda S, Fukushi Y, Habuchi T, Ohyama C, Arai Y; Tohoku Evidence-Based Medicine Study Group; Michinoku Urological Cancer Study Group. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar;19(1):57-62. doi: 10.1038/pcan.2015.50. Epub 2015 Oct 27. PMID: 26503109.
Narita S, Koie T, Yamada S, Orikasa K, Matsuo S, Aoki H, Ishidoya S, Hoshi S, Tsuchiya N, Ohyama C, Arai Y, Habuchi T. A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer. Jpn J Clin Oncol. 2016 Jun;46(6):547-553. doi: 10.1093/jjco/hyw021. Epub 2016 Mar 8. PMID: 26962246.
Narita T, Koie T, Ookubo T, Mitsuzuka K, Narita S, Yamamoto H, Inoue T, Hatakeyama S, Kawamura S, Tochigi T, Habuchi T, Arai Y, Ohyama C. The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis. Med Oncol. 2017 Jan;34(1):1. doi: 10.1007/s12032-016-0859-0. Epub 2016 Nov 26. PMID: 27889880.
Narita T, Hatakeyama S, Yoneyama T, Narita S, Yamashita S, Mitsuzuka K, Sakurai T, Kawamura S, Tochigi T, Takahashi I, Nakaji S, Tobisawa Y, Yamamoto H, Koie T, Tsuchiya N, Habuchi T, Arai Y, Ohyama C. Clinical implications of serum N-glycan profiling as a diagnostic and prognostic biomarker in germ-cell tumors. Cancer Med. 2017 Apr;6(4):739-748. doi: 10.1002/cam4.1035. Epub 2017 Mar 20. PMID: 28317343; PMCID: PMC5387168.
Matsumoto T, Hatakeyama S, Ookubo T, Mitsuzuka K, Narita S, Inoue T, Yamashita S, Narita T, Koie T, Kawamura S, Tochigi T, Tsuchiya N, Habuchi T, Arai Y, Ohyama C. Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi- institutional analysis. Med Oncol. 2017 Oct 31;34(12):190. doi: 10.1007/s12032-017-1050-y. PMID: 29090390.
Mitsuzuka K, Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol. 2018 Jan;25(1):45-53. doi: 10.1111/iju.13473. Epub 2017 Oct 20. PMID: 29052905.
Okubo T, Mitsuzuka K, Koie T, Hoshi S, Matsuo S, Saito S, Tsuchiya N, Habuchi T, Ohyama C, Arai Y; Michinoku Urological Cancer Study Group. Two years of bicalutamide monotherapy in patients with biochemical relapse after radical prostatectomy. Jpn J Clin Oncol. 2018 Jun 1;48(6):570-575. doi: 10.1093/jjco/hyy060. PMID: 29718346.
Yamamoto H, Koie T, Ookubo T, Mitsuzuka K, Narita S, Inoue T, Kawamura S, Kato T, Tochigi T, Tsuchiya N, Habuchi T, Arai Y, Ohyama C. Can single positive core prostate cancer at biopsy be considered a low-risk disease? Int Urol Nephrol. 2018 Oct;50(10):1829-1833. doi: 10.1007/s11255-018-1966-y. Epub 2018 Aug 20. PMID: 30128924.
Narita S, Nara T, Kanda S, Numakura K, Saito M, Inoue T, Satoh S, Nanjo H, Tsuchiya N, Mitsuzuka K, Koie T, Kawamura S, Ohyama C, Tochigi T, Arai Y, Habuchi T. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis. Clin Genitourin Cancer. 2019 Feb;17(1):e113-e122. doi: 10.1016/j.clgc.2018.09.019. Epub 2018 Sep 27. PMID: 30391137.
Akamatsu S, Kubota M, Uozumi R, Narita S, Takahashi M, Mitsuzuka K, Hatakeyama S, Sakurai T, Kawamura S, Ishidoya S, Hoshi S, Ishida M, Mizuno K, Ogura K, Goto T, Terada N, Kobayashi T, Yamasaki T, Inoue T, Tsuchiya N, Ohyama C, Arai Y, Habuchi T, Morita S, Ogawa O. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration- sensitive Metastatic Prostate Cancer. Eur Urol Oncol. 2019 May;2(3):320-328. doi: 10.1016/j.euo.2018.10.011. Epub 2018 Nov 23. PMID: 31200847.
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. Sci Rep. 2019 Aug 19;9(1):12071. doi: 10.1038/s41598-019-48600-8. PMID: 31427687; PMCID: PMC6700107.
Okamoto T, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan. World J Urol. 2019 Sep;37(9):1827-1835. doi: 10.1007/s00345-018-2590-2. Epub 2018 Dec 4. PMID: 30511214.
Hamano I, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer. World J Urol. 2019 Nov;37(11):2365-2373. doi: 10.1007/s00345-019-02664-3. Epub 2019 Feb 7. PMID: 30729312.
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy. Cancer Med. 2019 Nov;8(15):6566-6577. doi: 10.1002/cam4.2502. Epub 2019 Sep 11. PMID: 31508900; PMCID: PMC6825980.
Kodama H, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Narita T, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer. Clin Genitourin Cancer. 2019 Dec;17(6):e1091-e1098. doi: 10.1016/j.clgc.2019.05.029. Epub 2019 Sep 10. PMID: 31575477.
Okamoto T, Hatakeyama S, Narita S, Arai Y, Habuchi T, Ohyama C. Validation and development of the CHAARTED criteria in patients with hormone-naïve metastatic prostate cancer: A multi-institutional retrospective study in Japan. Int J Urol. 2020 Jan;27(1):90-91. doi: 10.1111/iju.14136. Epub 2019 Oct 15. PMID: 31617248.
Okita K, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Ito A, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study. Clin Genitourin Cancer. 2020 Apr;18(2):e103-e111. doi: 10.1016/j.clgc.2019.09.006. Epub 2019 Sep 27. PMID: 31810867.
Narita S, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Koizumi A, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nomura K, Habuchi T. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan. Int J Clin Oncol. 2020 May;25(5):912-920. doi: 10.1007/s10147-019-01614-8. Epub 2020 Jan 9. PMID: 31919691.
Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Hamano I, Okamoto T, Mitsuzuka K, Ito A, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration- sensitive prostate cancer: A multicenter retrospective study. Int J Urol. 2020 Jul;27(7):610-617. doi: 10.1111/iju.14258. Epub 2020 May 16. PMID: 32418347.
Narita T, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Shimoda J, Kawaguchi T, Ishidoya S, Mitsuzuka K, Arai Y, Ito A, Tsuchiya N, Habuchi T, Ohyama C. Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis. Transl Androl Urol. 2021 Jan;10(1):417-425. doi: 10.21037/tau-20-966. PMID: 33532329; PMCID: PMC7844496.
Iwamura H, Hatakeyama S, Narita S, Arai Y, Habuchi T, Ohyama C. Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: A retrospective multicenter study. Int J Urol. 2021 Jan;28(1):125-127. doi: 10.1111/iju.14392. Epub 2020 Oct 8. PMID: 33034051.
Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Tsushima E, Nishiyama H, Ito A, Kojima Y, Habuchi T, Obara W, Tsuchiya N, Ohyama C. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study. Int J Urol. 2021 Apr;28(4):369-375. doi: 10.1111/iju.14466. Epub 2020 Dec 12. PMID: 33314387.
Okamoto T, Noro D, Hatakeyama S, Narita S, Mitsuzuka K, Sakurai T, Kawamura S, Hoshi S, Shimoda J, Tanaka T, Kawaguchi T, Ishidoya S, Ito A, Tsuchiya N, Habuchi T, Ohyama C. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study. BMC Cancer. 2021 May 25;21(1):605. doi: 10.1186/s12885-021-08206-8. PMID: 34034691; PMCID: PMC8152305.
Matsuda Y, Narita S, Okubo T, Mitsuzuka K, Hatakeyama S, Koizumi A, Koie T, Kawamura S, Tochigi T, Ito A, Oyama C, Arai Y, Habuchi T. Impact of Nerve- Sparing Status on Positive Surgical Margin Location and Biochemical Recurrence in Patients with Prostate Cancer Post Radical Prostatectomy. Ann Surg Oncol. 2021 Sep;28(9):5341-5348. doi: 10.1245/s10434-021-10281-x. Epub 2021 Jun 9. PMID: 34109511.
Naito S, Kato T, Numakura K, Hatakeyama S, Koguchi T, Kandori S, Kawasaki Y, Adachi H, Kato R, Narita S, Yamamoto H, Ogawa S, Kawamura S, Obara W, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. Int J Clin Oncol. 2021 Oct;26(10):1947-1954. doi: 10.1007/s10147-021-01979-9. Epub 2021 Jun 30. PMID: 34191191.
Okita K, Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Nishiyama H, Ito A, Kojima Y, Habuchi T, Obara W, Tsuchiya N, Ohyama C. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study. Urol Oncol. 2021 Dec;39(12):836.e11-836.e17. doi: 10.1016/j.urolonc.2021.08.015. Epub 2021 Sep 17. PMID: 34544649.
Numakura K, Muto Y, Naito S, Hatakeyama S, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Obara W, Ohyama C, Tsuchiya N, Habuchi T. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era. Cancer Med. 2021
Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. Int J Clin Oncol. 2022 Mar;27(3):563-573. doi: 10.1007/s10147-021-02091-8. Epub 2022 Jan 1. Erratum in: Int J Clin Oncol. 2023 May;28(5):726-727. PMID: 34973106; PMCID: PMC8882566.
Morozumi K, Mitsuzuka K, Narita S, Takahashi M, Kawamura S, Tochigi T, Arai Y, Hoshi S, Shimoda J, Ishidoya S, Okamoto T, Hatakeyama S, Sakurai T, Tsuchiya N, Ohyama C, Habuchi T, Ito A. Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8. Int J Urol. 2022 Apr;29(4):324-331. doi: 10.1111/iju.14781. Epub 2022 Jan 18. PMID: 35042278.
Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Nomura K, Habuchi T. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy. World J Urol. 2022 May;40(5):1135-1141. doi: 10.1007/s00345-022-03963-y. Epub 2022 Feb 26. PMID: 35218371.
Sobu R, Numakura K, Naito S, Hatakeyama S, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Obara W, Ohyama C, Tsuchiya N, Habuchi T. Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study. Cancer Med. 2023 Feb;12(4):4100-4109. doi: 10.1002/cam4.5268. Epub 2022 Oct 6. PMID: 36200612; PMCID: PMC9972009.
